Shopping Cart 0
Cart Subtotal
USD 0

NeuroDerm Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

NeuroDerm Ltd (NeuroDerm), a subsidiary of Mitsubishi Tanabe Pharma Corp, is a pharmaceutical company that develops of drugs for the treatment of Parkinson's disease and central nervous system (CNS) disorders through proprietary reformulations of its existing drugs. The company's liquid formulation of levodopa/carbidopa product candidates includes ND0612L, intended for moderate Parkinson's diseases; and ND0612H, for severe Parkinson's disease. It also develops ND0701, intended for patients with severe Parkinson's disease and ND0801, a product candidate intended for the treatment of cognitive disorders associated with CNS diseases including attention deficit disorder or attention deficit hyperactivity disorder, schizophrenia, alzheimer's disease, and other diseases. NeuroDerm is headquartered in Rehovot, Israel.

NeuroDerm Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

NeuroDerm Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

NeuroDerm Ltd, Medical Devices Deals, 2012 to YTD 2018 9

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

NeuroDerm Raises USD16 Million in Venture Financing 11

Equity Offering 12

NeuroDerm Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD86.3 Million 12

NeuroDerm Raises USD77 Million in Public Offering of Shares 14

NeuroDerm Raises USD45 Million in IPO 16

Acquisition 18

Mitsubishi Tanabe Pharma Acquires Neuroderm for USD1.1 Billion 18

NeuroDerm Ltd-Key Competitors 20

NeuroDerm Ltd-Key Employees 21

NeuroDerm Ltd-Locations And Subsidiaries 22

Head Office 22

Recent Developments 23

Financial Announcements 23

Aug 03, 2017: NeuroDerm Announces Second Quarter 2017 Financial Results 23

May 11, 2017: NeuroDerm Announces First Quarter 2017 Financial Results 24

Mar 30, 2017: NeuroDerm Announces Fourth Quarter and Full Year 2016 Financial Results 26

Clinical Trials 28

Jun 27, 2017: Results of NeuroDerm's ND0612H Phase II Trial Presented in Oral Session at the 3rd Congress of the European Academy of Neurology 28

Jun 08, 2017: NeuroDerm Presents Posters on its Clinical Pipeline Program ND0701 at the 21st International Congress of Parkinson's Disease and Movement Disorders 29

Jun 08, 2017: NeuroDerm Presents Posters on levodopa/carbidopa liquid formulation at the 21st International Congress of Parkinson's Disease and Movement Disorders 31

Jun 06, 2017: European Medicines Agency Accepts Design of NeuroDerm's ND0612 Phase III iNDiGO Efficacy Trial 32

Jun 05, 2017: NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster Session at the 21st International Congress of Parkinson's Disease and Movement Disorders 33

May 23, 2017: NeuroDerm ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at the 21st International Congress of Parkinson's Disease and Movement Disorders 35

Mar 01, 2017: NeuroDerm Achieves Primary Endpoint in ND0612H Phase II Trial for Advanced Parkinson's Disease; Seeks Broader EU Label Based on iNDiGO Trial Following EMA Meeting 36

Appendix 39

Methodology 39

About GlobalData 39

Contact Us 39

Disclaimer 39


List Of Figure

List of Figures

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

NeuroDerm Ltd, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Key Facts 2

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

NeuroDerm Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

NeuroDerm Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

NeuroDerm Ltd, Medical Devices Deals, 2012 to YTD 2018 9

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

NeuroDerm Raises USD16 Million in Venture Financing 11

NeuroDerm Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD86.3 Million 12

NeuroDerm Raises USD77 Million in Public Offering of Shares 14

NeuroDerm Raises USD45 Million in IPO 16

Mitsubishi Tanabe Pharma Acquires Neuroderm for USD1.1 Billion 18

NeuroDerm Ltd, Key Competitors 20

NeuroDerm Ltd, Key Employees 21

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

NeuroDerm Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

NeuroDerm Ltd (NeuroDerm), a subsidiary of Mitsubishi Tanabe Pharma Corp, is a pharmaceutical company that develops of drugs for the treatment of Parkinson's disease and central nervous system (CNS) disorders through proprietary reformulations of its existing drugs. The company's liquid formulation of levodopa/carbidopa product candidates includes ND0612L, intended for moderate Parkinson's diseases; and ND0612H, for severe Parkinson's disease. It also develops ND0701, intended for patients with severe Parkinson's disease and ND0801, a product candidate intended for the treatment of cognitive disorders associated with CNS diseases including attention deficit disorder or attention deficit hyperactivity disorder, schizophrenia, alzheimer's disease, and other diseases. NeuroDerm is headquartered in Rehovot, Israel.

NeuroDerm Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

NeuroDerm Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

NeuroDerm Ltd, Medical Devices Deals, 2012 to YTD 2018 9

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

NeuroDerm Raises USD16 Million in Venture Financing 11

Equity Offering 12

NeuroDerm Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD86.3 Million 12

NeuroDerm Raises USD77 Million in Public Offering of Shares 14

NeuroDerm Raises USD45 Million in IPO 16

Acquisition 18

Mitsubishi Tanabe Pharma Acquires Neuroderm for USD1.1 Billion 18

NeuroDerm Ltd-Key Competitors 20

NeuroDerm Ltd-Key Employees 21

NeuroDerm Ltd-Locations And Subsidiaries 22

Head Office 22

Recent Developments 23

Financial Announcements 23

Aug 03, 2017: NeuroDerm Announces Second Quarter 2017 Financial Results 23

May 11, 2017: NeuroDerm Announces First Quarter 2017 Financial Results 24

Mar 30, 2017: NeuroDerm Announces Fourth Quarter and Full Year 2016 Financial Results 26

Clinical Trials 28

Jun 27, 2017: Results of NeuroDerm's ND0612H Phase II Trial Presented in Oral Session at the 3rd Congress of the European Academy of Neurology 28

Jun 08, 2017: NeuroDerm Presents Posters on its Clinical Pipeline Program ND0701 at the 21st International Congress of Parkinson's Disease and Movement Disorders 29

Jun 08, 2017: NeuroDerm Presents Posters on levodopa/carbidopa liquid formulation at the 21st International Congress of Parkinson's Disease and Movement Disorders 31

Jun 06, 2017: European Medicines Agency Accepts Design of NeuroDerm's ND0612 Phase III iNDiGO Efficacy Trial 32

Jun 05, 2017: NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster Session at the 21st International Congress of Parkinson's Disease and Movement Disorders 33

May 23, 2017: NeuroDerm ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at the 21st International Congress of Parkinson's Disease and Movement Disorders 35

Mar 01, 2017: NeuroDerm Achieves Primary Endpoint in ND0612H Phase II Trial for Advanced Parkinson's Disease; Seeks Broader EU Label Based on iNDiGO Trial Following EMA Meeting 36

Appendix 39

Methodology 39

About GlobalData 39

Contact Us 39

Disclaimer 39


List Of Figure

List of Figures

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

NeuroDerm Ltd, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Key Facts 2

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

NeuroDerm Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

NeuroDerm Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

NeuroDerm Ltd, Medical Devices Deals, 2012 to YTD 2018 9

NeuroDerm Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

NeuroDerm Raises USD16 Million in Venture Financing 11

NeuroDerm Completes Underwriters Exercise of Over-Allotment Option of Public Offering for USD86.3 Million 12

NeuroDerm Raises USD77 Million in Public Offering of Shares 14

NeuroDerm Raises USD45 Million in IPO 16

Mitsubishi Tanabe Pharma Acquires Neuroderm for USD1.1 Billion 18

NeuroDerm Ltd, Key Competitors 20

NeuroDerm Ltd, Key Employees 21

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

NeuroDerm Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.